Objective. An atherogenic lipid profile is an established risk factor for cardiovascular diseases (CVD).
INTRODUCTION
Rheumatoid arthritis (RA) is a chronic inflammatory joint disease affecting approximately 1% of the general population.(1) RA patients suffer from an elevated cardiovascular (CV) morbidity and mortality as compared with the general population. (2) (3) (4) . The excess of CV disease (CVD) in RA patients is predominantly due to accelerated atherosclerosis (5) . Dyslipidaemia is a well recognized risk factor for atherosclerosis and has increasing been acknowledged in RA, mostly in untreated RA patients. (6) (7) (8) (9) (10) Recent studies suggest an initial, transient, improvement of the lipid profile by pivotal anti-inflammatory drugs like tumour necrosis factor (TNF) blocking agents, (11) (12) (13) (14) whereas a recent meta-analysis showed a modest effect on total cholesterol and high density lipoprotein (HDL) cholesterol with no overall effect on the atherogenic index (i.e. total cholesterol : HDL cholesterol ratio) after 26 weeks. (15) More intriguing was the recently described favourable alteration in HDL composition in ankylosing spondylitis patients upon TNF blockade. This study observed the acute phase reactant serum amyloid A (SAA) to disappear from the HDL particle, thereby increasing the atheroprotective ability of the HDL particle. (16) . Information about effects of newer biological drugs as B cell depletion therapy (RTX) on cholesterol metabolism is sparse. (17;18) In randomised clinical trials RTX decreases disease activity in approximately 60 to 65% of RA patients failing to respond on TNF blocking agents. (19) By targeting CD20 positive B lymphocytes, RTX results in B cell depletion by inducing apoptosis. This process is dependent on the presence and conformation of lipid rafts, containing CD20, within the cell membrane of CD20 positive cells. As statins change the conformation of these CD20 containing lipid rafts, antiCD20 therapy with RTX might be impaired in patients using statins. (20) Recently, the inhibiting effect of statins on the antirheumatic effects of RTX has been described in RA patients participating in a Dutch prospective registry study of 187 RA patients, probably as a result of conformation change. (21) From this viewpoint statins might, hypothetically, not be the first drug of choice for cardiovascular risk management in RTX treated patients as it is unknown whether the atheroprotective capacities of statins will be outweighed by the negative effects on disease activity status with subsequent inflammation mediated dyslipidaemia. In this context it is important to study the effects of RTX on the lipid profile to exclude detrimental effects of RTX on lipid metabolism in RA patients.
Therefore, we studied changes in lipids and HDL protein composition upon six months RTX treatment in RA patients.
PATIENTS AND METHODS

Study population
Consecutive RA patients, according to the 1988 revised American College of Rheumatology criteria for the diagnosis of RA, attending the outpatients clinics of the VU University Medical Center and Jan van Breemen Research Institute│Reade scheduled for rituximab were followed prospectively. (22) Inclusion criteria for this study are according to the guidelines of the Dutch Society for Rheumatology for treatment with rituximab, i.e. active disease status (defined as 28 joint disease activity score (DAS28) > 3.2 at treatment initiation) despite previous treatment with TNF-blocking agents, unless contraindicated in the opinion of the treating physician, and previous treatment with methotrexate (MTX) and one other disease modifying antirheumatic drug (DMARD). All patients provided written informed consent and both participating clinics received approval by the local medical ethics committee.
Treatment and follow up
Patients received RTX 1,000 mg intravenously on days 1 and 15, in combination with clemastine (2 mg intravenously), methylprednisolone (100 mg intravenously) and acetaminophen 1,000 mg orally, as premedication. Four weeks after the first infusion and from 12 weeks onwards every 3 months patients the DAS28.(23) After 6 months the change in DAS28 was assessed and expressed as clinical response according to EULAR response criteria.(24) At all visits blood sampling for collection of serum and plasma was performed. The use of concomitant DMARDs, prednisolone or non-steroidal antiinflammatory drugs (NSAIDs) during the study duration was permitted.
Assessment of lipids
Serum total cholesterol and triglycerides were analyzed by an enzymatic method using the appropriate assays (Roche Diagnostics, Almere, The Netherlands), on a Cobas 6000 analyzer (Roche Diagnostics), according to the manufacturer's instructions. The HDL cholesterol is determined enzymmatically by cholesterol esterase and cholesterol oxidase coupled with polyethylene glycol to the amino groups. In this oxidation reaction a purple-blue dye will be formed and its' intensity correlates to cholesterol concentration, which can be measured photometrically. Apolipoprotein (Apo) A-I and Apo B were analyzed by an immunoturbidimetric method, using appropriate assays (Roche Diagnostics). The Friedewald formula was used to calculate Low density lipoprotein (LDL) levels, when triglyceride levels were lower than 4.5 mmol/l, the total cholesterol/HDL-c (atherogenic index) and Apo B/Apo A-I ratios were calculated.
HDL cholesterol protein profiling
To detect HDL composition changes between responders and non responders during RTX treatment we selected from our cohort the 6 best responding patients (defined as DAS28 < 3.2 and ΔDAS28 > 1.2) and 6 patients with absence of response (defined as DAS28 > 5.2 and ΔDAS28 < 1.2 6 months after RTX). In this subgroup a pilot HDL protein profiling study was performed as described Buffered Saline (pH 7.4, 5 minutes for each wash), followed by a 2-minute rinse with TBS-Tween (0.005%). A final wash step with HEPES solution (5 mM) was carried out to remove the excess salt. All spots were allowed to dry, and subsequently, 1.2 μl of sinapinic acid (10 mg/ml) in a 50:49.9:0.1% acetonitrile-water-trifluoric acid mix was applied onto each spot. All chips were air-dried and stored at room temperature in the dark until analysis. The measurements were conducted on the same day as the chip processing.
Surface-enhanced laser desorption/ionization time-of-flight (SELDI-TOF) analysis
The reliability of the SELDI-TOF MS technique as such has been under debate recently. Since protein profiling and not the identification of proteins was the major goal we have chosen for this approach because of it's strong applicability in high throughput sample measurement. Data on the reproducibility and clinical applicability of the SELDI technique as used here have been extensively reported previously and were the basis of our experimental setup as used in this study. (25;26) In brief, SELDI-TOF analysis of the captured HDL was carried out using a PBS IIc protein chip reader (Ciphergen Biosystems, Fremont, CA). An automated data collection protocol within the Protein-Chip software (version 3.1) was used. Data were collected up to 160 kDa. Laser intensity was set in a range of 190-220 arbitrary units at a sensitivity of 7, and the focus mass was set at 28 kd, specific for antiApo A-I capture. Measurement of the spectra was performed with an average of 100 shots at 13 positions per SELDI spot. Calibration was done using a protein calibration chip (Ciphergen). Spectra were normalized on Apo A-I peak area. Detected peaks having a signal-to-noise ratio of 5 were recognized as significant peaks.
Statistical analyses
Baseline characteristics of RA patients were expressed as mean (±SD) or median (interquartile range 
RESULTS
Characteristics and clinical response of RA patients
Baseline characteristics of rituximab treated RA patients (n = 49) are shown in table 1. Thirty two (65%) showed response according to EULAR response criteria. In the total group the mean DAS28 decreased significantly from 5.7 (± 1.3) to 4.5 (± 1.3) and 4.7 (± 1.6), respectively after 3 and 6 months (all p < 0.001). In responders 13% were statin users compared to 18% in non responders.
During treatment statin users had a higher mean DAS28 score (~0.8 points, p for trend = 0.075).
None of the patients initiated lipid lowering therapy during follow up. 
Cholesterol changes in the total group
In the total group levels of HDL and Apo A-I levels increased and the atherogenic index and Apo 
Cholesterol changes in responders upon rituximab
No significant changes in cholesterol levels were observed in non responders. In responders (n = 32) total cholesterol, HDL cholesterol, apo A-I and Apo B/Apo A-I ratios changed significantly after 1 month of treatment of RTX (table 3) . Adjustment for other covariates did not change the observed effects. After 3 months triglycerides and Apo B/Apo A-I ratios changed significantly. Six months after RTX HDL cholesterol changed ~5%, Apo A-I ~5%, atherogenic index ~7% and the Apo B/Apo A-I ratio ~9% (p = 0.035). The observed effects of these cholesterol profiles did not change after adjustment for confounding factors (data not shown). 
Lipids, disease activity and prednisone
The association between lipid levels and markers of disease activity are shown in table 4. No significant association was observed between prednisone dosage and lipid levels. In contrast, significant associations were observed between changes in DAS28 on the one hand and changes in 
SELDI-TOF analysis in responders versus non responders during treatment
Characteristics of proteome analysed RA patients are shown in 
DISCUSSION
This study shows favorable effects in the atherogenic index and the Apo B/Apo A-I ratio of RA patients treated with RTX. Along with these beneficial effects on the lipid profile, functional alterations are observed in HDL particle protein composition, i.e. from proatherogenic to a less proinflammatory and less proatherogenic composition in good responding patients during treatment, as shown by a decline in SAA concentration on the HDL particle during RTX treatment.
This prospective study is by far the largest report that studies alterations in lipid levels during RTX treatment in RA. The first study in pilot setting performed in only 6 RA patients described an increase in total cholesterol, HDL cholesterol and LDL cholesterol levels, especially two weeks after RTX initiation. (17) Another pilot study in 5 RA patients observed significant improvement of HDL cholesterol (18) In line with these reports the present study shows a borderline significant (p = 0.054) improvement of the atherogenic index (~9%) and non significant increase in HDL cholesterol (~5%) in the total group after 6 months treatment RTX. Moreover, in good responding RTX patients a significant improvement of the Apo B/Apo A-I ratio and a (non significant) improvement of HDL cholesterol and atherogenic index was observed. Moreover, this study demonstrates significant associations between the acute phase reactant CRP and lipid levels, hence, the observed changes are at least partly explained by the decline in inflammation. These results underline the importance of tight control with antiinflammatory treatment in RA as low disease activity not only decelerates radiologic progression,(28) but also seems to improve the cardiovascular risk profile by an, albeit limited, improvement of the atherogenic index in a patient group prone to CVD development.
In addition, to the long term effects during RTX treatment, early effects (i.e. 1 month after RTX initiation) on lipid levels were observed, and did not sustain after 3 months, as was previous effects of pulsed high dose methylprednisolone on lipid levels. Therefore, it seems plausible that the initial effects on lipid levels during RTX treatment are at least partially explained by concomitant glucocorticoid use as premedication. (32) Although the observed changes in lipid levels were small, it is remarkable that this study demonstrates significant improvement of Apo B/Apo A-I ratio and the atherogenic index, as a recent meta analysis of our group described significant parallel increases in total and HDL cholesterol levels and no overall effect on the atherogenic index during TNF blocking therapy. (15) In contrast, in the present study we observed a significant improvement of the atherogenic index with a decline to ~ 3.8, i.e. below the threshold (4.0) by some considered desirable.(33) Moreover, the increase of HDL during lipid lowering drugs was estimated on approximately 5%, comparable to the effect in this study during RTX treatment, and previous reports demonstrated that 6% increase in HDL levels will result in an absolute risk reduction of ~4.5% of (non) fatal coronary heart diseases.(34;35) Although data about patients using statins can not be directly extrapolated to RA patients, amongst others due to heterogeneity in populations, more pleiotropic and pivotal cardioprotective effects of statins, these results ensure at least no detrimental effect of RTX on lipid levels and favour a mild beneficial long term effect of RTX on lipid levels.
Next to the quantitative changes in lipid levels, we performed SELDI-TOF MS analysis to study HDL To what extent these baseline differences fully explain the dynamics in HDL composition, can not be assessed with the current study design and sample size. On the other hand, the observation of a significant reduction of 7 additional proteins or protein fragments (which remain to be identified) underlines the dynamics of the HDL protein particle composition as a consequence of changes in inflammatory status during anti-inflammatory treatment. Therefore, we encourage new studies in high CVD risk patients groups like RA to focus on inflammation and functional capacities of HDL in relation to atherosclerosis. Moreover, it remains an intriguing question whether the proteins found at baseline serve as predictor for RTX response.
In conclusion, this study shows at least no detrimental effect on lipid levels upon 6 months RTX treatment and favours late beneficial effects on the cholesterol profile along with improvement of disease activity. Proteomic HDL particle profiling revealed composition changes from proatherogenic to a less proinflammatory and less proatherogenic composition during RTX. These results emphasize the need for unravelling the function of HDL composition in inflammatory rheumatic disorders in relation to cardiovascular outcome.
